Abbott Laboratories (NYSE:ABT) headquartered in Abbott Park, will host a conference call for the investment community to discuss the 2Q20 financial results on 16th July 2020 at 9:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.abbott.com
An archived edition of the call will be available later that day.
An archived edition of the call will be available later that day.
Earnings Expectation
Abbott Laboratories is reporting second quarter financial results on Thursday 16th July 2020, before market open.
According to analysts surveyed by Thomson Reuters, ABT is expected to report 2Q20 income of $ 0.41 per share from revenue of $ 6749.42 million.
For the full year, analysts anticipate top line of $ 31360.70 million, while looking forward to income of $ 2.84 per share bottom line.
The Company Outlook
Full Year 2020 bottomline are predicted in a range of $ 3.55 ~ $ 3.65 per share
Click Here For More Historical Outlooks Of Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The companys Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménières disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories.
